GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (BSP:B1MR34) » Definitions » Cyclically Adjusted Book per Share

Biomarin Pharmaceutical (BSP:B1MR34) Cyclically Adjusted Book per Share : R$55.06 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Biomarin Pharmaceutical Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Biomarin Pharmaceutical's adjusted book value per share for the three months ended in Mar. 2024 was R$66.569. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is R$55.06 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Biomarin Pharmaceutical's average Cyclically Adjusted Book Growth Rate was 10.60% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 14.60% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 14.70% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 18.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Biomarin Pharmaceutical was 28.40% per year. The lowest was 13.20% per year. And the median was 18.30% per year.

As of today (2024-06-07), Biomarin Pharmaceutical's current stock price is R$210.00. Biomarin Pharmaceutical's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was R$55.06. Biomarin Pharmaceutical's Cyclically Adjusted PB Ratio of today is 3.81.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Biomarin Pharmaceutical was 27.64. The lowest was 3.43. And the median was 8.89.


Biomarin Pharmaceutical Cyclically Adjusted Book per Share Historical Data

The historical data trend for Biomarin Pharmaceutical's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Cyclically Adjusted Book per Share Chart

Biomarin Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 36.24 48.33 50.43 51.99

Biomarin Pharmaceutical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 50.32 49.02 53.74 51.99 55.06

Competitive Comparison of Biomarin Pharmaceutical's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Biomarin Pharmaceutical's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomarin Pharmaceutical's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Biomarin Pharmaceutical's Cyclically Adjusted PB Ratio falls into.



Biomarin Pharmaceutical Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biomarin Pharmaceutical's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=66.569/131.7762*131.7762
=66.569

Current CPI (Mar. 2024) = 131.7762.

Biomarin Pharmaceutical Quarterly Data

Book Value per Share CPI Adj_Book
201406 11.114 100.560 14.564
201409 11.960 100.428 15.693
201412 13.537 99.070 18.006
201503 23.768 99.621 31.440
201506 22.776 100.684 29.809
201509 27.752 100.392 36.428
201512 28.841 99.792 38.085
201603 26.101 100.470 34.234
201606 20.102 101.688 26.050
201609 25.065 101.861 32.426
201612 26.870 101.863 34.761
201703 24.986 102.862 32.009
201706 26.284 103.349 33.514
201709 25.110 104.136 31.775
201712 26.315 104.011 33.340
201803 26.051 105.290 32.604
201806 30.646 106.317 37.985
201809 33.661 106.507 41.647
201812 32.330 105.998 40.193
201903 31.499 107.251 38.702
201906 31.813 108.070 38.792
201909 35.258 108.329 42.889
201912 35.632 108.420 43.308
202003 43.790 108.902 52.988
202006 46.352 108.767 56.157
202009 60.308 109.815 72.369
202012 58.116 109.897 69.686
202103 64.196 111.754 75.697
202106 58.173 114.631 66.874
202109 61.343 115.734 69.846
202112 65.580 117.630 73.467
202203 59.093 121.301 64.196
202206 61.307 125.017 64.622
202209 64.457 125.227 67.828
202212 64.820 125.222 68.213
202303 64.677 127.348 66.926
202306 61.691 128.729 63.151
202309 64.204 129.860 65.152
202312 64.321 129.419 65.492
202403 66.569 131.776 66.569

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Biomarin Pharmaceutical  (BSP:B1MR34) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Biomarin Pharmaceutical's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=210.00/55.06
=3.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Biomarin Pharmaceutical was 27.64. The lowest was 3.43. And the median was 8.89.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Biomarin Pharmaceutical Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomarin Pharmaceutical (BSP:B1MR34) Business Description

Traded in Other Exchanges
Address
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.

Biomarin Pharmaceutical (BSP:B1MR34) Headlines

No Headlines